Semaglutide shows no significant benefit on cognitive decline in early Alzheimer's disease (EVOKE Plus) trial
Background
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, with limited effective treatments. Current therapies primarily manage symptoms rather than halting disease progression. Growing evidence suggests a link between metabolic dysfunction, insulin resistance, and neuroinflammation in AD pathogenesis, leading researchers to investigate drugs like GLP-1 receptor agonists. These agents, such as semaglutide, are known for their glucose-lowering, anti-inflammatory, and potential neuroprotective effects, making them a candidate for repurposing in early AD.
Study Design
This Phase 3, randomized, double-blind, placebo-controlled clinical trial (EVOKE Plus) investigated the effect and safety of oral semaglutide in subjects with early Alzheimer's disease. Participants were randomized to receive either semaglutide or placebo. The semaglutide arm initiated treatment with 0.05 mg/day for 4 weeks, escalating every 4 weeks to a target dose of 0.4 mg/day. The study duration was up to 173 weeks (approximately 3 years and 4 months), involving 17 clinic visits and 1 phone call. Primary endpoints included changes in the Clinical Dementia Rating Sum of Boxes (CDR-SB) score. A cerebrospinal fluid (CSF) sub-study was also conducted at selected sites for exploratory endpoints.
Results
The EVOKE Plus trial, alongside its sister study EVOKE, did not demonstrate a significant positive effect of semaglutide on cognitive decline in early Alzheimer's disease. For EVOKE Plus, the mean change in CDR-SB score from baseline to week 104 was 2.2 (SE 0.1) with semaglutide, compared with 2.1 (SE 0.1) with placebo. The estimated difference between semaglutide and placebo was 0.10 (95% CI -0.17 to 0.38), with a p-value of p=0.46. This indicates no statistically significant difference in cognitive function improvement or slowing of decline between the treatment and placebo groups. The combined analysis of EVOKE and EVOKE+ also showed no significant difference.
The primary endpoint, change in
CDR-SBscore, showed no statistically significant benefit for semaglutide over placebo in early Alzheimer's disease (p=0.46).
Key Findings
- Semaglutide did not significantly improve
CDR-SBscores compared to placebo in early Alzheimer's disease. - Mean change in
CDR-SBscore at week 104 was 2.2 for semaglutide vs. 2.1 for placebo in EVOKE Plus. - The estimated difference in
CDR-SBchange was 0.10 (95% CI -0.17 to 0.38) with a p-value of p=0.46 for EVOKE Plus. - The study duration was up to 173 weeks, with dose escalation to a target of 0.4 mg/day oral semaglutide.
Why It Matters
This study provides important evidence that oral semaglutide, at the tested dose and duration, does not significantly impact cognitive decline in individuals with early Alzheimer's disease. For individuals exploring metabolic interventions for neurodegeneration, this suggests that GLP-1 agonism alone, via semaglutide, may not be sufficient to alter the disease course in early AD. While the metabolic link to AD remains an active area of research, this specific approach did not yield positive results on the primary clinical endpoint. Future research may need to explore different GLP-1 agonists, higher doses, longer durations, combination therapies, or target different stages of AD to identify effective strategies.
semaglutide
alzheimer's-disease
cognitive-decline
phase-3-trial
glp-1-agonist
neurodegeneration